Novavax (NVAX) Current Leases (2012 - 2026)
Novavax (NVAX) posted quarterly Current Leases of $2.1 million for Q1 2026, down 61.45% year-over-year from $5.5 million in Q1 2025, and down 15.76% quarter-over-quarter from $2.5 million in Q4 2025.
Novavax (NVAX) Current Leases (2012 - 2026) Analysis & Trends
Novavax's Current Leases history runs 10 years deep, the most recent figure standing at $2.1 million for Q1 2026.
- In Q1 2026, Current Leases fell 61.45% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $2.1 million (down 61.45% YoY), while the FY2025 annual figure was $2.5 million, down 64.23% from the prior year.
- Current Leases for Q1 2026 stood at $2.1 million, down from $2.5 million in the prior quarter.
- The five-year high for Current Leases was $124.3 million in Q2 2022, with the low at $953000.0 in Q2 2023.
- The 5-year median for Current Leases is $5.6 million (2025), against an average of $25.2 million.
- The sharpest annual moves came in 2023 and 2024: Current Leases tumbled 99.23% in 2023, then surged 889.19% in 2024.
- Novavax's Current Leases stood at $44.1 million in 2022, then sank by 88.33% to $5.1 million in 2023, then jumped by 36.31% to $7.0 million in 2024, then tumbled by 64.23% to $2.5 million in 2025, then slipped by 15.76% to $2.1 million in 2026.
- Business Quant data shows NVAX's Current Leases at $2.1 million in Q1 2026, $2.5 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 4.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.11 Mn |
| Mar 31, 2026 | 2.11 Mn |
| Dec 31, 2025 | 2.51 Mn |
| Sep 30, 2025 | 5.04 Mn |
| Jun 30, 2025 | 5.55 Mn |
| Mar 31, 2025 | 5.48 Mn |
| Dec 31, 2024 | 7.01 Mn |
| Sep 30, 2024 | 9.68 Mn |
| Jun 30, 2024 | 9.43 Mn |
| Mar 31, 2024 | 6.29 Mn |
| Dec 31, 2023 | 5.14 Mn |
| Sep 30, 2023 | 1.33 Mn |
| Jun 30, 2023 | 953,000.00 |
| Mar 31, 2023 | 1.21 Mn |
| Dec 31, 2022 | 44.06 Mn |
| Sep 30, 2022 | 82.10 Mn |
| Jun 30, 2022 | 124.26 Mn |
| Mar 31, 2022 | 116.68 Mn |
| Dec 31, 2021 | 161.52 Mn |
| Sep 30, 2021 | 103.99 Mn |